Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.92
NAS:ZGNX's Cash to Debt is ranked higher than
55% of the 778 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.15 vs. NAS:ZGNX: 5.92 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ZGNX' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 1.75 Max: N/A
Current: 5.92
Equity to Asset 0.58
NAS:ZGNX's Equity to Asset is ranked lower than
57% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NAS:ZGNX: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ZGNX' s Equity to Asset Range Over the Past 10 Years
Min: -3.87  Med: 0.16 Max: 0.61
Current: 0.58
-3.87
0.61
F-Score: 2
Z-Score: -0.78
M-Score: -2.76
WACC vs ROIC
14.58%
-103.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -222.12
NAS:ZGNX's Operating margin (%) is ranked lower than
91% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.44 vs. NAS:ZGNX: -222.12 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ZGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -299.29  Med: -155.85 Max: 142.89
Current: -222.12
-299.29
142.89
Net-margin (%) -198.81
NAS:ZGNX's Net-margin (%) is ranked lower than
91% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. NAS:ZGNX: -198.81 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ZGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -313.81  Med: -165.1 Max: 96.18
Current: -198.81
-313.81
96.18
ROE (%) -32.46
NAS:ZGNX's ROE (%) is ranked lower than
84% of the 753 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.76 vs. NAS:ZGNX: -32.46 )
Ranked among companies with meaningful ROE (%) only.
NAS:ZGNX' s ROE (%) Range Over the Past 10 Years
Min: -491.54  Med: -398.45 Max: 23.3
Current: -32.46
-491.54
23.3
ROA (%) -18.39
NAS:ZGNX's ROA (%) is ranked lower than
81% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. NAS:ZGNX: -18.39 )
Ranked among companies with meaningful ROA (%) only.
NAS:ZGNX' s ROA (%) Range Over the Past 10 Years
Min: -164.96  Med: -84.9 Max: 10.28
Current: -18.39
-164.96
10.28
ROC (Joel Greenblatt) (%) -357.34
NAS:ZGNX's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.07 vs. NAS:ZGNX: -357.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ZGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -508.05  Med: -356.62 Max: 350.09
Current: -357.34
-508.05
350.09
Revenue Growth (3Y)(%) -34.00
NAS:ZGNX's Revenue Growth (3Y)(%) is ranked lower than
94% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. NAS:ZGNX: -34.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ZGNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -62.2 Max: -34
Current: -34
EBITDA Growth (3Y)(%) -15.20
NAS:ZGNX's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 564 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.30 vs. NAS:ZGNX: -15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ZGNX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -73.05 Max: -15.2
Current: -15.2
EPS Growth (3Y)(%) -25.60
NAS:ZGNX's EPS Growth (3Y)(%) is ranked lower than
85% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NAS:ZGNX: -25.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ZGNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -71.05 Max: -25.6
Current: -25.6
» NAS:ZGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ZGNX Guru Trades in Q3 2015

Steven Cohen 3,800 sh (New)
Jim Simons 135,287 sh (+536.31%)
» More
Q4 2015

ZGNX Guru Trades in Q4 2015

Paul Tudor Jones 16,613 sh (New)
Jim Simons 136,887 sh (+1.18%)
Steven Cohen Sold Out
» More
Q1 2016

ZGNX Guru Trades in Q1 2016

Paul Tudor Jones 16,400 sh (-1.28%)
Jim Simons 74,087 sh (-45.88%)
» More
Q2 2016

ZGNX Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Jim Simons 37,187 sh (-49.81%)
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:AGYTF, NAS:BITI, OTCPK:RAQUF, NAS:RMTI, NAS:NBRV, NAS:ASMB, NAS:OASM, AMEX:NNVC, OTCPK:BIOYF, OTCPK:FAMDF, NAS:ALIM, OTCPK:PXSLY, OTCPK:CKDXY, AMEX:AXN, NAS:NVGN, NAS:PRPH, OTCPK:CHEXF, OTCPK:INNV, OTCPK:SUWN, NAS:ALQA » details
Traded in other countries:Z081.Germany,
Zogenix Inc is a pharmaceutical company engaged in commercializing & developing therapies that address clinical needs for people living with pain-related and CNS disorders that needs treatment alternatives to help return to normal daily functioning.

Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA. Its trademarks include DosePro, Relday, Zogenix and Zohydro ER. The Company is subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or FFDCA, and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Ratios

vs
industry
vs
history
P/B 1.75
ZGNX's P/B is ranked higher than
73% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. ZGNX: 1.75 )
Ranked among companies with meaningful P/B only.
ZGNX' s P/B Range Over the Past 10 Years
Min: 1.15  Med: 4.66 Max: 543.53
Current: 1.75
1.15
543.53
P/S 9.79
ZGNX's P/S is ranked lower than
79% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. ZGNX: 9.79 )
Ranked among companies with meaningful P/S only.
ZGNX' s P/S Range Over the Past 10 Years
Min: 0.3  Med: 5.29 Max: 14.79
Current: 9.79
0.3
14.79
Current Ratio 10.58
ZGNX's Current Ratio is ranked higher than
91% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. ZGNX: 10.58 )
Ranked among companies with meaningful Current Ratio only.
ZGNX' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.73 Max: 10.58
Current: 10.58
0.85
10.58
Quick Ratio 9.74
ZGNX's Quick Ratio is ranked higher than
91% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. ZGNX: 9.74 )
Ranked among companies with meaningful Quick Ratio only.
ZGNX' s Quick Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.44 Max: 9.74
Current: 9.74
0.32
9.74
Days Inventory 180.03
ZGNX's Days Inventory is ranked lower than
76% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.00 vs. ZGNX: 180.03 )
Ranked among companies with meaningful Days Inventory only.
ZGNX' s Days Inventory Range Over the Past 10 Years
Min: 180.03  Med: 226.42 Max: 419.33
Current: 180.03
180.03
419.33
Days Sales Outstanding 29.10
ZGNX's Days Sales Outstanding is ranked higher than
86% of the 579 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.08 vs. ZGNX: 29.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.75  Med: 58.69 Max: 76.64
Current: 29.1
18.75
76.64
Days Payable 66.14
ZGNX's Days Payable is ranked lower than
52% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.81 vs. ZGNX: 66.14 )
Ranked among companies with meaningful Days Payable only.
ZGNX' s Days Payable Range Over the Past 10 Years
Min: 66.14  Med: 85.38 Max: 148.78
Current: 66.14
66.14
148.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -25.30
ZGNX's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. ZGNX: -25.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -348.1  Med: -32.9 Max: 0
Current: -25.3
-348.1
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.76
ZGNX's Price/Net Cash is ranked lower than
61% of the 201 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.90 vs. ZGNX: 20.76 )
Ranked among companies with meaningful Price/Net Cash only.
ZGNX' s Price/Net Cash Range Over the Past 10 Years
Min: 9.25  Med: 13.38 Max: 153.33
Current: 20.76
9.25
153.33
Price/Net Current Asset Value 7.95
ZGNX's Price/Net Current Asset Value is ranked higher than
51% of the 441 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.54 vs. ZGNX: 7.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ZGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.95  Med: 5.61 Max: 22.24
Current: 7.95
3.95
22.24
Price/Tangible Book 5.75
ZGNX's Price/Tangible Book is ranked lower than
62% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. ZGNX: 5.75 )
Ranked among companies with meaningful Price/Tangible Book only.
ZGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.82  Med: 6.71 Max: 470.59
Current: 5.75
2.82
470.59
Price/Median PS Value 1.86
ZGNX's Price/Median PS Value is ranked lower than
73% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. ZGNX: 1.86 )
Ranked among companies with meaningful Price/Median PS Value only.
ZGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 0.97 Max: 2.13
Current: 1.86
0.08
2.13
Earnings Yield (Greenblatt) (%) -33.82
ZGNX's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ZGNX: -33.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -38.63  Med: 34.3 Max: 20885.8
Current: -33.82
-38.63
20885.8

More Statistics

Revenue (TTM) (Mil) $26.50
EPS (TTM) $ -2.33
Beta1.76
Short Percentage of Float20.12%
52-Week Range $7.33 - 16.56
Shares Outstanding (Mil)24.79

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 19 15 18 46
EPS ($) -3.41 -2.96 -2.56 -0.99
EPS w/o NRI ($) -3.41 -2.96 -2.56 -0.99
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ZGNX

Headlines

Articles On GuruFocus.com
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
ZOGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 27 2016
Zogenix to Participate in Two Upcoming Investor Conferences Sep 20 2016
Zogenix to Participate in Two Upcoming Investor Conferences Sep 20 2016
ETF’s with exposure to Zogenix, Inc. : September 15, 2016 Sep 15 2016
Zogenix to have Significant Presence at 12th European Congress on Epileptology Sep 08 2016
Zogenix to have Significant Presence at 12th European Congress on Epileptology Sep 08 2016
ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 26 2016
ZOGENIX, INC. Financials Aug 19 2016
ETF’s with exposure to Zogenix, Inc. : August 15, 2016 Aug 15 2016
Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Why This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas Aug 12 2016
Zogenix reports 2Q loss Aug 09 2016
Zogenix reports 2Q loss Aug 09 2016
Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results Aug 09 2016
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 09 2016
Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results Aug 09 2016
Q2 2016 Zogenix Inc Earnings Release - After Market Close Aug 09 2016
Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on... Aug 02 2016
Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on... Aug 02 2016
ZOGENIX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)